Viral-like structured DNA and RNA assemblies, also known as DNA and RNA origami, offer the ability to co-formulate gene-length single-stranded DNA or mRNA with CRISPR-RNPs, siRNAs, or ASOs, with the integration of active cellular targeting, stimulation, and uptake moieties including peptides, sugars, and small molecules. Biological stability and immunostimulation can additionally be programmed selectively through the use of chemical modifications. Scaleable bacterial production of custom length and sequence single-stranded DNA offers a low-cost path towards clinical-scale production. Here, I will present our lab’s formulation and preclinical work in the context of the field, to produce pre-clinical scale, endotoxin-free structured DNA and RNA assemblies for targeted delivery of nucleic acid gene therapeutics and vaccines, including a case study of viral-like DNA assemblies applied to an HIV vaccine candidate.